Janux Therapeutics, Inc. (JANX) Dividend History

Company News

• Why Janux Therapeutics Crushed the Market Today

  Janux Therapeutics stock rose nearly 12% after an analyst raised his price target, though he maintained a 'sector perform' rating. The company also launched a $300 million secondary stock offering to advance its cancer treatment pipeline.

  The Motley Fool
• The Latest Analyst Ratings For Janux Therapeutics

  Throughout the last three months, 9 analysts have evaluated Janux Therapeutics (NASDAQ:JANX), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $68.22, a high estimate of $100.00, and a low estimate of $47.00. This current average has increased by 68.44% from the previous average price target of $40.50. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive Janux Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target George Farmer Scotiabank Announces Sector Perform $47.00 - Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $63.00 $50.00 Josh Schimmer Cantor Fitzgerald Maintains Overweight $100.00 - Robert Driscoll Wedbush Raises Outperform $74.00 $53.00 Soumit Roy JonesTrading Announces Buy $70.00 - Kaveri Pohlman BTIG Announces Buy $62.00 - Josh Schimmer Cantor Fitzgerald Announces Overweight $100.00 - Geoff Meacham B of A Securities Raises Buy $48.00 $24.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $50.00 $35.00 Key Insights: Action ...Full story available on Benzinga.com

  Benzinga
• Analyst Ratings For Janux Therapeutics

  In the preceding three months, 9 analysts have released ratings for Janux Therapeutics (NASDAQ:JANX), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 4 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 2 0 0 0 2M Ago 1 1 0 0 0 3M Ago 2 1 0 0 0 Analysts have set 12-month price targets for Janux Therapeutics, revealing an average target of $68.89, a high estimate of $100.00, and a low estimate of $48.00. Witnessing a positive shift, the current average has risen by 85.19% from the previous average price target of $37.20. Decoding Analyst Ratings: A Detailed Look The standing of Janux Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $63.00 $50.00 Josh Schimmer Cantor Fitzgerald Maintains Overweight $100.00 - Robert Driscoll Wedbush Raises Outperform $74.00 $53.00 Soumit Roy JonesTrading Announces Buy $70.00 - Kaveri Pohlman BTIG Announces Buy $62.00 - Josh Schimmer Cantor Fitzgerald Announces Overweight $100.00 - Geoff Meacham B of A Securities Raises Buy $48.00 $24.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $50.00 $35.00 David Driscoll Wedbush Raises Outperform $53.00 $24.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.com

  Benzinga
• Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates

  Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: RYTM
• Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength

  Janux Therapeutics (JANX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

  Zacks Investment Research